MindMed to Participate in June Conferences

Rhea-AI Summary

MindMed (NASDAQ: MNMD), a clinical stage biopharmaceutical company focusing on brain health disorders, announced its participation in two significant June conferences. The first is the BIO International Convention 2024 in San Diego, CA, where they will join the panel 'Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation' on June 4, 2024. The second is the Jefferies 2024 Global Healthcare Conference in New York, NY, where they will engage in 1x1 investor meetings on June 5-6, 2024.

Positive

• Participation in high-profile conferences could increase visibility and attract new investors.
• Involvement in discussions on neuropsychiatric drug innovation may position MindMed as a thought leader in the field.
• 1x1 investor meetings at Jefferies 2024 Global Healthcare Conference may lead to new investment opportunities.

Negative

• No new clinical data or financial results were disclosed, leaving investors without updated performance information.
• The focus on conferences without tangible business updates may be seen as insufficient for investor reassurance.

NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences:

• BIO International Convention 2024
  • Panel Name: Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation
  • Date and Time: Tuesday, June 4, 2024 at 4:15 pm PDT
  • Location: San Diego, CA

• Jefferies 2024 Global Healthcare Conference
  • Format: 1x1 investor meetings only
  • Dates: June 5-6, 2024
  • Location: New York, NY

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528659571/en/

For Media: media@mindmed.co

For Investors: ir@mindmed.co

Source: Mind Medicine Inc.

FAQ

What events will MindMed (MNMD) participate in June 2024?

MindMed will participate in the BIO International Convention 2024 on June 4 and the Jefferies 2024 Global Healthcare Conference on June 5-6.

What is the significance of MindMed's (MNMD) participation in the BIO International Convention 2024?

MindMed will join a panel discussing neuropsychiatric drug innovation, highlighting their role in advancing brain health treatments.

What will MindMed (MNMD) do at the Jefferies 2024 Global Healthcare Conference?

MindMed will engage in 1x1 investor meetings, potentially securing new investments.

When and where will MindMed (MNMD) present at the BIO International Convention 2024?

MindMed will participate on June 4, 2024, in San Diego, CA.

What is the focus of MindMed's (MNMD) panel at the BIO International Convention 2024?

The panel will discuss 'Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation.'